Mantle cell lymphoma trials in China

In China 41 Also abroad 151

41 trials · From ClinicalTrials.gov, checked 12 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma
Where
Guangzhou
Age
18 years to 70 years
People
30
Run by
Sun Yat-sen University
See details and how to joinNCT07077512
Phase 4Not yet taking people in China
ZSDT for the Treatment of R/R Mantle Cell Lymphoma After BTK Inhibitor Failure: a Multi-center Prospective Clinical Trial
Where
Zhengzhou
Age
18 years to 70 years
People
30
Run by
Zhengzhou University
See details and how to joinNCT07264894
No phaseTaking people
Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma
Where
Beijing
Age
18 years to 80 years
People
34
Run by
Peking University Third Hospital
See details and how to joinNCT07257510
Phase 2Not yet taking people in China
Chemotherapy Combined With Targeted Therapy as First-line Treatment for Mantle Cell Lymphoma Based on MRD and PET-CT Assessment
Where
Fuzhou, Harbin, Jinan, Shijiazhuang, Tianjin
Age
60 years and over
People
45
Run by
Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT07206264
Phase 2Taking people
Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment
Where
Shanghai
Age
14 years and over
People
45
Run by
Ruijin Hospital
See details and how to joinNCT07199296
Phase 1Not yet taking people in China
JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma
Where
Beijing
Age
18 years and over
People
20
Run by
Peking University Cancer Hospital & Institute
See details and how to joinNCT07024147
Phase 2Taking people
Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma
Where
Guangzhou
Age
18 years and over
People
50
Run by
Sun Yat-sen University
See details and how to joinNCT06846489
Phase 1Taking people
Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma
Where
Hangzhou
Age
18 years to 75 years
People
52
Run by
Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT06464861
Phase 3Taking people
A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
Where
Beijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Luoyang, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Ürümqi, Wuhan, Xi'an, Yibin, Zhengzhou
Age
60 years and over
People
476 worldwide
Run by
InnoCare Pharma Inc.
See details and how to joinNCT06363994 · EU 2025-524241-27-00
Phase 2Taking people
A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell Lymphoma
Where
Shanghai
Age
18 years and over
People
52
Run by
Fudan University
See details and how to joinNCT06341556
Phase 3Taking people
Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment
Where
Shanghai
Age
18 years to 80 years
People
78
Run by
Ruijin Hospital
See details and how to joinNCT06496308
Phase 2Not yet taking people in China
Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma.
Where
Dalian
Age
18 years and over
People
10
Run by
Dalian Medical University
See details and how to joinNCT06324994
Phase 2Not yet taking people in China
A Single-arm, Single-center, Open-label Phase II Study of Zanubrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle CellLymphoma Patients
Where
Taiyuan
Age
18 years to 70 years
People
23
Run by
Shanxi Province Cancer Hospital
See details and how to joinNCT06255704
Phase 2Taking people
A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma
Where
Shanghai
Age
18 years and over
People
23
Run by
Ruijin Hospital
See details and how to joinNCT06136351
Phase 2Taking people
ZR2 Sequential Immunochemotherapy for Newly Treated MCL
Where
Hangzhou
Age
18 years to 75 years
People
48
Run by
Zhejiang Cancer Hospital
See details and how to joinNCT05992597
No phaseTaking people
A Clinical Study of Hanlikang and BTK Inhibitors in the Treatment of Newly Diagnosed Mantle Cell Lymphoma
Where
Zhengzhou
Age
18 years to 90 years
People
100
Run by
Zhengzhou University
See details and how to joinNCT05506410